Wednesday, September 12, 2018 10:36:51 PM
Madrigal Pharmaceuticals: Fast climber
This biotech came out of nowhere to take a leading position in the NASH dash with solid data for MGL-3196 late last year. The company followed up in May with results that suggest it will give Ocaliva a challenge. During a mid-stage study, 27% of patients treated with MGL-3196 achieved NASH resolution versus just 6% of those treated with a placebo.
Intercept is months away from wrapping up Ocaliva's pivotal NASH trial, but Madrigal hasn't even started one yet. When Madrigal checked in last, management was still waiting for the FDA to sign off on the company's pivotal trial design.
At recent prices Madrigal sports a $3.5 billion market cap that could soar in the long run if MGL-3196 repeats previous observations without any safety issues, but investors need to understand that it could also come crashing down if there's any trouble with its lead candidate. There's nothing in the company's pipeline to fall back on.
Mid-stage results left no doubt that MGL-3196 lowers liver fat content for patients, but we still don't know a lot about the drug's safety profile. No troubling safety issues reared their ugly heads during the mid-stage study that propelled Madrigal into the spotlight, but there were only 107 patients in the trial.
https://finance.yahoo.com/news/3-top-stocks-investing-pharma-131700454.html
GO MDGL
"PEACE"
Recent MDGL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 01:51:22 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/11/2024 01:29:06 AM
- Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/26/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:16:25 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 11:52:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 12:58:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:06:32 AM
- Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel • GlobeNewswire Inc. • 08/02/2024 11:00:21 AM
- Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 • GlobeNewswire Inc. • 07/24/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 01:39:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/15/2024 01:44:36 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 09:17:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 08:37:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/13/2024 09:53:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 09:03:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/11/2024 09:39:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 10:48:25 PM
- Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress • GlobeNewswire Inc. • 06/06/2024 12:00:00 PM
- Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 01:36:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:36:01 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM